PCN22 COSTS OF COMMON TREATMENT OPTIONS FOR INDOLENT FOLLICULAR NON-HODGKIN'S LYMPHOMA  by Van Agthoven, M et al.
A40 Abstracts
nisms had a substantial impact on the results of health economic
evaluations.
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OBJECTIVES: Follicular non-Hodgkin’s lymphoma (FL) is the
most common indolent lymphoma occurring in the Western
Hemisphere with a variable clinical course. Because of high costs
of new treatments, we assessed direct health care costs associ-
ated with the most commonly prescribed treatments for FL.
METHODS: New and previously diagnosed FL patients (>18
years) known during 1997–1998 to 15 Dutch hospitals were ran-
domly selected for inclusion. Each patient was followed for three
years, from a distinct event in the disease course onwards, for
resource use associated with each of the treatments, including
‘watchful waiting’. The hospital perspective was adopted. Unit
costs were based on the 2003 price level. RESULTS: Two
hundred patients were included, of whom 75% percent under-
went >1 treatment during the 3-year data collection period (25%
was not treated because of a watchful waiting strategy (10%) or
complete remission (15%)). Allogeneic and autologous stem cell
transplantations were the most expensive treatments, with a
mean per patient cost of €45,326 (n = 7) and €18,866 (n = 9)
respectively (up to discharge only). This was followed by ﬂu-
darabine i.v. €10,651 (n = 33), rituximab (€10,628; n = 7), and
CHOP €7547 (n = 42). Classical FL treatments were found to
be the least expensive treatments used with an estimated cost for
CVP of €5268 (n = 58), for radiotherapy of €4218 (n = 52), and
for chlorambucil of €2476 (n = 53). CONCLUSIONS: This study
presents detailed information on resource use and costs associ-
ated with the most commonly prescribed FL treatments. In addi-
tion to differences in effectiveness, commonly used treatments
vary considerably in terms of resource use and overall cost. This
information is of value for resource planning.
PCN23
ECONOMIC ASPECTS AND DRIVERS OF FEBRILE
NEUTROPENIA IN CANCER—A MULTICENTRE
RETROSPECTIVE ANALYSIS IN BELGIUM
Moeremans K, Caekelbergh K, Spaepen E,Annemans L
IMS Health, Brussels, Belgium
OBJECTIVES: To determine costs and identify cost drivers for
febrile neutropenia (FNE) in Belgium. METHODS: Direct costs
of FNE to health care payers were calculated from retro–pro-
jected chart review of patients treated during 2003 in 4 centres
(n = 93, 4 Hodgkin’s disease (HD), 36 Non–Hodgkin lymphoma
(NHL), 10 multiple myeloma, 35 breast cancer (BRCA) and 8
small–cell lung cancer). Clinical data and FNE related resource
utilization were collected from patient ﬁles. Cost data included
all FNE related costs. Resource use (including hospitalisation,
antimicrobials, perfusions, lab tests, interventions and other
drugs) was multiplied with unit costs from ofﬁcial sources.
Regression analysis to identify cost drivers was performed on
log–transformed costs using a mixed linear model. RESULTS:
The average number of FNE’s in patients with FNE was 1.3, the
ﬁrst FNE occurring after 1.7 cycles. The average number of
FNE’s tended to be higher in patients with hematological malig-
nancies and in patients receiving combination chemotherapy.
The mean cost per FNE episode, excluding G–CSF treatment and
secondary prevention, was €4221 (95% CI:3521–4921). Major
cost components were hospitalization (€2707), antimicrobial
therapy (€784) and tests (€636). Growth factors were prescribed
for FNE treatment and secondary prevention in 84% and 51%
of patients respectively. The average total cost of growth factors
was €2197. Mortality during chemotherapy was 11%. Regres-
sion analysis showed that underlying disease and survival were
independent cost drivers. NHL patients incurred 1.85 times
higher costs than others (95% CI:1.07–3.20, p = 0.0316).
Patients who died, either from FNE or from their underlying
disease, showed 1.52 times higher costs (95% CI:1.04–2.22, p =
0.0347) than survivors. Co–existence of thrombocytopenia or
anemia also signiﬁcantly predicted higher FNE costs. CON-
CLUSION: The cost of FNE varied according to underlying
disease. NHL patients showed the most elevated total FNE
related costs. These analyses of cost drivers enable to ﬁne–tune
data for economic analyses to relevant patient subgroup.
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OBJECTIVES: To estimate cost associated with informal care
giving in advanced stage Non-Small Cell Lung Cancer (NSCLC)
patients, identifying the costs drivers in Italy; to measure symp-
toms evolution using the LCS subscale of the FACT-L question-
naire. METHODS: A total of 104 patients (55 on second line
chemotherapy and 49 in supportive care) were enrolled in 18
Italian oncology departments and followed up for 3 months.
Main caregiver workload was assessed monthly by evaluating
the number of hours devoted to ten care giving tasks, presence
and activities of other informal or formal caregiver were regis-
tered, performance status was evaluated monthly by means of
the ECOG scale. Patients completed the LCS symptoms subscale
for each visit. Formal care giving time was valued according to
market prices; informal care giving hours were valued using the
wage rate for an equivalent service. The covariance analysis was
performed to check for inﬂuential factors in assistance need and
costs. RESULTS: During the 3-month observational period both
ECOG and LCS scores depreciated in the two groups. An equal
number of deaths were registered among patients in chemother-
apy and in supportive care. Monthly hours of informal care
giving increased from 124.37 to 166.9 for the chemotherapy
patients and from 141.92 to 150.97 for supportive care patients.
The whole home assistance cost accounted for €3159 for
chemotherapy and €4189 for supportive care patient. The regres-
sion analysis highlighted that symptom depreciation is a driver
of care giving time and costs and that the assistance cost
increases if the caregiver doesn’t live with the patient. CON-
CLUSIONS: The burden of assistance in NSCLC advanced
patients is mainly beard by family members who provide also
home health aide. As the population ages and family structure is
changing, social intervention targeted at unpaid family caregiver
will be needed to ease the economic, psychological and physical
burden of care giving.
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